2024-12-03 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison & Outperformance:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products.  The cumulative return for LLY is 631.05%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 130.06%. The difference in cumulative returns is 501.0 percentage points.  The relative outperformance, considering historical volatility, places LLY at the 74.4th percentile of its historical performance range against the S&P 500.  The provided alpha values consistently hover around zero, suggesting the stock's returns are largely explained by market movements (high beta). However, the consistently high CAGR demonstrates significant growth over the periods shown.


**2. Recent Price Movement:**

* **Closing Price:** $795.35 (Last Market: $799.13)
* **5-Day Moving Average:** $775.17
* **20-Day Moving Average:** $782.74
* **60-Day Moving Average:** $863.23

The stock price is currently below all three moving averages, suggesting a potential downward trend in the short to medium term.  The significant difference between the current price and the 60-day moving average is notable.  The closing price of $799.13 is slightly above the closing price.  There is no indication of a dramatic recent price movement (neither a significant upturn or downturn).

**3. Technical Indicators & Expected Return:**

* **RSI:** 40.64 (Slightly below the oversold threshold of 30, suggesting potential for a bounce, but not a strong buy signal)
* **PPO:** 0.74 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence:**  nan (-) indicates a recent short-term downward trend.
* **Expected Return:** 573.4% (This represents a significant projected long-term outperformance against the S&P 500,  but this projection needs to be treated cautiously due to its uncertainty).


**4. Recent Earnings Analysis:**

The provided earnings data shows significant volatility in EPS.  Revenue growth isn't consistently upward; there are fluctuations from quarter to quarter.  While there are substantial revenue numbers, a proper analysis requires understanding the context of these numbers, like expectations and market conditions.  A direct comparison of EPS between quarters shows significant variation (Q2 2024 EPS is markedly higher than other quarters).  The negative EPS in late 2023 and again in October 2024 is a notable point requiring further investigation.

**5. Financial Information Analysis:**

* **Revenue:** Revenue shows some fluctuation, but generally maintains a high level. The September 2024 quarter shows the highest reported revenue.
* **Profit Margin:**  Profit margins remain consistently high (around 80%), indicating strong profitability.
* **Equity & ROE:** Equity has generally grown. ROE fluctuates significantly, ranging from a loss to exceeding 20%, indicating variations in profitability and efficiency across quarters.  Understanding the drivers behind these fluctuations is crucial for a deeper analysis.

**6. News and Recent Issues:**

* **Earnings News:**  No specific earnings news within the last two days is provided. More detailed news sources would be needed to provide current market sentiment.
* **Market Outlook:**  Not provided.
* **Analyst Opinions:**  Not provided.


**7.  Overall Analysis Summary:**

LLY shows remarkably strong historical outperformance compared to the S&P 500, with a significantly higher cumulative return.  However, recent price action suggests a potential short-term downward trend, while technical indicators offer mixed signals.  Earnings data shows volatility in EPS and fluctuating revenue growth, which requires further analysis to understand the underlying drivers of performance.  High and stable profit margins are positive signs.  The high projected long-term expected return should be viewed with caution given its inherent uncertainty.  A more complete analysis would require information on analyst ratings, future projections, and broader market context.


**8. Disclaimer:** This report is based solely on the data provided. It does not constitute financial advice.  Conduct thorough research and consult with a financial advisor before making any investment decisions.
